Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease.

Drugs Context · 2021 · PMC7813433 · PMID 33505478

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Even if the results did not reach statistical significance, 33% of patients with ASS responded to RTX compared to 9.5% in SSc and 16.7% in MCTD; RTX presented an acceptable safety profile. 38 Among myositis-specific antibodies, antimelanoma differentiation-associated gene 5 antibody (anti-MDA5) is significantly associated with ILD.

also in 111,027 other papers

showed a trendno p-value reported

Furthermore, DLCO also showed a trend in improvement in the RTX group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.